查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736504

三價流感疫苗市場－依疫苗類型、年齡層、通路、地區分類的全球市場規模及預測－2020 年

Global Trivalent Flu Vaccine Market Size By Type of Vaccine (Inactivated Influenza Vaccines, Live Attenuated Influenza Vaccines ), By Age Group, By Distribution Channel, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格
簡介目錄

三價流感疫苗市場規模及預測

2024 年三價流感疫苗市場規模為 63.6 億美元，預計到 2032 年將達到 95.9 億美元，2026 年至 2032 年的複合年成長率為 5.80%。

推動全球三價流感疫苗市場的因素

三價流感疫苗市場的促進因素可能受到多種因素的影響。這些因素包括：

流感病毒株的流行：疫苗接種需求直接受到流感病毒株（尤其是三價疫苗所預防的病毒株）的流行程度和嚴重程度的影響。流行病毒株的變化可能導致疫苗成分和需求的改變。

政府建議與法規：流感疫苗產品的市場需求可能受到政府法規和衛生當局建議的顯著影響。可以透過公共衛生宣傳活動提高流感疫苗接種覆蓋率。

醫療基礎設施和認知：獲得醫療服務以及對流感疫苗接種價值的認知至關重要。改善醫療設施和開展教育活動可以提高疫苗接種覆蓋率，從而推動市場擴張。

季節性變化與疫情：流感疫苗接種需求可能會因季節性、偶發性或大流行性流感而增加。 COVID-19 疫情等事件也可能影響流感疫苗的需求和認知度。

技術發展：疫苗生產技術的發展，例如基於細胞和重組疫苗製造，可能會透過提高疫苗有效性、降低生產成本和增加供給能力來影響市場。

人口因素：疫苗需求可能受到年齡分佈和流感併發症易感性等因素的影響。老年人、幼兒和長期患病者等高危險群可能會推動需求。

醫療費用和保險覆蓋：流感疫苗的費用和可近性受醫療費用和保險覆蓋的影響。隨著保險覆蓋範圍和報銷標準的擴大，疫苗接種率可能會提高。

競爭格局：生產三價流感疫苗的製藥公司之間的競爭可能會影響產品創新、定價和分銷管道。

全球化與旅行：隨著世界旅行和全球化的增加，流感病毒已在​​世界範圍內傳播，增加了流感疫苗接種的需求。

限制全球三價流感疫苗市場的因素

多種因素可能對三價流感疫苗市場造成限制和挑戰。這些因素包括：

疫苗有效性：三價流感疫苗的有效性可能因疫苗與目前流行的病毒株的相似程度而異。疫苗與常見株之間的差異可能會降低疫苗效力，並削弱大眾對疫苗宣傳活動的信心。

對疫苗安全性的擔憂：對疫苗成分安全性和副作用的擔憂可能會使人們猶豫是否接種疫苗。錯誤訊息會影響人們對疫苗安全性的認知，導致人們產生疫苗猶豫。

醫療服務可近性有限：醫療服務可近性有限，尤其是在農村和服務不足地區，可能會阻礙疫苗的分發和接種。成本、交通途徑以及衛生系統缺陷等因素可能會阻礙疫苗的接種。

其他疫苗的競爭：三價疫苗市場可能會受到其他流感疫苗劑型（例如滴鼻劑和四價疫苗）的競爭影響。為了維持市場佔有率，製造商需要使其產品差異化，並證明其更安全、更有效。

監管難題：製造商必須承擔成本並面臨行政管理難題，以遵守有關疫苗接種授權、生產標準和上市後監管的法規。監管程序的延誤和不確定性可能會阻礙市場准入和擴張。

全球經濟狀況：景氣衰退或經濟低迷可能會影響衛生支出重點，從而導致疫苗接種計畫的預算限制，並降低消費者自掏腰包接種疫苗的意願。

疫苗猶豫：疫苗猶豫會削弱大眾對流感疫苗的信心，並因錯誤訊息、對醫療機構的不信任和文化觀念等因素而阻礙市場擴張。

疫苗供應鏈中斷，包括原料短缺、製造過程中的問題或分銷困難，可能導致供不應求或延遲，並影響市場上疫苗的可用性和可及性。

疫情疲勞：儘管人們對疫情帶來的風險有了更多的了解，但對流感和疫苗宣傳活動的冷漠或疲勞可能會降低接種流感疫苗的緊迫性，尤其是在流感活動較低的時期。

目錄

第1章全球三價流感疫苗市場介紹

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球三價流感疫苗市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球三價流感疫苗市場（依疫苗類型）

  • 概述
  • 去活化流感疫苗（IIV）
  • 減毒活流感疫苗（LAIV）
  • 重組流感疫苗

6. 全球三價流感疫苗市場（依年齡層）

  • 概述
  • 兒童疫苗
  • 成人疫苗
  • 老年人疫苗

7. 全球三價流感疫苗市場（依分銷管道）

  • 概述
  • 醫院和診所
  • 藥局
  • 公共衛生項目

8. 全球三價流感疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

9. 全球三價流感疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第10章 公司簡介

  • AstraZeneca
  • Sanofi SA
  • Abbott
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Johnson & Johnson
  • Serum Institute of India
  • CSL Limited

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 37130

Trivalent Flu Vaccine Market Size And Forecast

Trivalent Flu Vaccine Market size was valued at USD 6.36 Billion in 2024 and is projected to reach USD 9.59 Billion by 2032, growing at a CAGR of 5.80% from 2026 to 2032.

Global Trivalent Flu Vaccine Market Drivers

The market drivers for the Trivalent Flu Vaccine Market can be influenced by various factors. These may include:

Influenza Strain Prevalence:The demand for the vaccination is directly impacted by the frequency and severity of influenza strains, especially those that are protected by the trivalent vaccine. Variations in vaccine composition and demand can be caused by changes in circulating strains.

Government Recommendations and Regulations:The market demand for flu vaccine products can be greatly impacted by government regulations and recommendations made by health authorities. Uptake rates of the flu vaccination can be increased via public health campaigns.

Healthcare Infrastructure and Awareness:Having access to healthcare services and being aware of the value of getting vaccinated against the flu are essential. Enhanced healthcare facilities and education initiatives can raise immunization rates, which will propel market expansion.

Seasonal changes and Epidemics:Flu vaccination demand may rise in response to seasonal changes in flu outbreaks as well as sporadic epidemics or pandemics. The demand for and awareness of flu vaccinations can also be influenced by events like the COVID-19 pandemic.

Technological Developments:By increasing vaccine efficacy, lowering production costs, and increasing supply capacity, developments in vaccine manufacturing technology, such as cell-based or recombinant vaccine production, can have an impact on the market.

Demographic Factors:The demand for vaccines can be influenced by factors such as age distribution and vulnerability to complications from the flu. Demand may be driven by high-risk demographics like the elderly, small children, and people with long-term medical issues.

Healthcare Costs and Insurance Coverage:The cost and availability of flu shots are influenced by healthcare costs and insurance coverage. Vaccination rates can rise as a result of expanded insurance coverage and reimbursement guidelines.

Competitive Landscape:The rivalry between pharmaceutical firms producing trivalent flu shots can have an impact on product innovation, pricing, and distribution routes.

Globalization and Travel:As a result of increased worldwide travel and globalization, influenza viruses are spreading around the world, increasing the need for flu vaccinations.

Global Trivalent Flu Vaccine Market Restraints

Several factors can act as restraints or challenges for the Trivalent Flu Vaccine Market. These may include:

Vaccine Efficacy: Depending on how closely the vaccine resembles the viral strains that are currently in circulation, the effectiveness of trivalent flu shots can differ. Inconsistencies between the vaccine and common strains might diminish effectiveness and erode public trust in immunization campaigns.

Vaccine Safety Concerns: People may be discouraged from getting vaccinated due to worries about the safety of the vaccine's ingredients or side effects, which could affect the market's uptake. Misinformation can affect people's perceptions of vaccine safety, which can result in vaccine hesitation.

Restricted Access to Healthcare Services: Distribution and administration of vaccines may be hampered by limited access to healthcare services, especially in rural or underserved areas. The uptake of vaccines may be hampered by obstacles like cost, transportation, and deficiencies in the healthcare system.

Competition from Other vaccinations:The market for trivalent vaccinations may be impacted by competition from other flu vaccine formulations, such as nasal spray or quadrivalent vaccines. To retain market share, manufacturers need to set their products apart and show that they are safer or more effective.

Regulatory Difficulties: Manufacturers must incur money and bear administrative difficulties in order to comply with regulations pertaining to vaccination licensing, manufacturing standards, and post-market surveillance. Market entry or expansion may be hampered by regulatory procedural delays or uncertainty.

Global Economic Situation: Recessions and downturns in the economy can have an impact on healthcare spending priorities, which can result in budgetary restrictions for immunization programs and a decline in the willingness of consumers to pay for vaccinations out of pocket.

Vaccine Hesitancy: Vaccine hesitancy can damage public confidence in flu vaccination and impede market expansion. It might be caused by disinformation, mistrust of healthcare authorities, or cultural views.

Disruptions in the vaccine supply chain, such as shortages of raw materials, problems during manufacturing, or difficulties with distribution, can result in shortages or delays in the supply, which can affect the accessibility and availability of the vaccine on the market.

Fatigue from Pandemic Preparedness: Even with heightened knowledge of the hazards posed by pandemics, apathy or fatigue with regard to influenza and vaccine campaigns might lessen the urgency of getting vaccinated against the flu, especially in times of low flu activity.

Global Trivalent Flu Vaccine Market Segmentation Analysis

The Global Trivalent Flu Vaccine Market is Segmented on the basis of Type of Vaccine, Age Group, Distribution Channel, and Geography.

Type of Vaccine:

Inactivated Influenza Vaccines (IIV): These vaccines contain killed influenza viruses and are administered via injection.

Live Attenuated Influenza Vaccines (LAIV): These vaccines contain weakened influenza viruses and are administered via nasal spray.

Recombinant Influenza Vaccines: These vaccines are produced by genetic engineering methods and do not require the use of flu virus.

Age Group:

Pediatric Vaccines: Designed for children, typically aged 6 months to 17 years.

Adult Vaccines: Targeted for individuals aged 18 to 64 years who do not fall into the pediatric or elderly categories.

Elderly Vaccines: Specifically formulated for individuals aged 65 years and above, who are at higher risk of flu-related complications.

Distribution Channel:

Hospitals and Clinics: Vaccines are distributed through healthcare facilities where they are administered by healthcare professionals.

Pharmacies: Vaccines are available for purchase and administration at retail pharmacies.

Public Health Programs: Distribution occurs through government-run vaccination campaigns and public health initiatives.

Geography:

North America: Market conditions and demand in the United States, Canada, and Mexico.

Europe: Analysis of the Trivalent Flu Vaccine Market in European countries.

Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.

Middle East and Africa: Examining market dynamics in the Middle East and African regions.

Latin America: Covering market trends and developments in countries across Latin America.

Key Players

Sanofi Pasteur

GlaxoSmithKline (GSK)

Seqirus

Merck & Co., Inc.

Pfizer Inc.

F. Hoffmann-La Roche Ltd.

CSL Limited

Mylan N.V.

AstraZeneca

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TRIVALENT FLU VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL TRIVALENT FLU VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL TRIVALENT FLU VACCINE MARKET, BY TYPE OF VACCINE

  • 5.1 Overview
  • 5.2 Inactivated Influenza Vaccines (IIV)
  • 5.3 Live Attenuated Influenza Vaccines (LAIV)
  • 5.4 Recombinant Influenza Vaccines

6 GLOBAL TRIVALENT FLU VACCINE MARKET, BY AGE GROUP

  • 6.1 Overview
  • 6.2 Pediatric Vaccines
  • 6.3 Adult Vaccines
  • 6.4 Elderly Vaccines

7 GLOBAL TRIVALENT FLU VACCINE MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospitals and Clinics
  • 7.3 Pharmacies
  • 7.4 Public Health Programs

8 GLOBAL TRIVALENT FLU VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL TRIVALENT FLU VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 AstraZeneca
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Sanofi S.A
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Abbott
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 GlaxoSmithKline
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Merck
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Novartis
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Pfizer
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Johnson & Johnson
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Serum Institute of India
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 CSL Limited
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research